Newly approved and limited data available. From SKYLIGHT 1 trial, treatment-emergent adverse reactions included headache and a small number of participants with abnormal ALT or AST.167 It is recommended to measure liver enzyme levels at baseline and monthly for the first 3 months, then at months 6 and 9 following initiation of treatment.168Contraindications: avoid in patients with cirrhosis, severe renal impairment, or end stage renal disease.Drug interactions—Fezolinetant is metabolized by CYP1A2 and should be avoided in patients on CYP1A2 inhibitors169. Here, CYP1A2 is linked to Cirrhosis.